Atrophoderma Vermiculata

Atrophoderma vermiculata is a rare skin condition that usually begins in childhood. It first shows up as tiny rough bumps centered on hair follicles, most often on the cheeks and sometimes the forehead or areas in front of the ears. Over time, the bumps settle down but leave behind shallow, small pits in a network pattern. When you look closely, the skin can seem “worm-eaten,” “honeycomb,” or “reticular” (net-like). The condition belongs to a small family of disorders called keratosis pilaris atrophicans. In all of these, a problem in how the skin sheds and renews cells around hair follicles leads to long-term thinning (atrophy) and scarring around those follicles. PubMed+2MDedge+2

Doctors diagnose atrophoderma vermiculata mainly by how it looks and where it appears. It is not an infection, it is not cancer, and it is not caused by acne bacteria. Instead, the main driver is abnormal keratinization—the skin’s dead cell layer builds up and plugs the hair opening. This can trigger small, long-lasting inflammation around the follicle. As the skin heals, it may leave small pits or depressions. The pitted pattern makes the cheeks look like a honeycomb. DermNet®+1

The condition is uncommon and often under-recognized. It most often starts in childhood, progresses slowly for several years, and then tends to stabilize. In many people, it causes cosmetic worry more than physical symptoms. Rarely, it can be seen together with other inherited or structural conditions, so your clinician may ask extra questions to rule those out. ScienceDirect+1

Other names

People and articles may use different names for the same condition. You might see:

• Atrophoderma vermiculata (most common medical name).

• Keratosis pilaris atrophicans faciei – atrophoderma variant (because it sits inside the keratosis pilaris atrophicans spectrum).

• “Honeycomb atrophy of the cheeks” (describes the pattern).

• “Worm-eaten” facial atrophy (another descriptive phrase).

• Some sources list it together with ulerythema ophryogenes (the eyebrow-thinning variant) and keratosis follicularis spinulosa decalvans (a scalp-involving variant) as close relatives in one spectrum. PubMed+1

Types

There isn’t a strict universal “type” list, but doctors often group cases by patterns that help clinical care:

1. Classic bilateral facial pattern – both cheeks (often with the pre-auricular area and sometimes the forehead) show fine pits in a honeycomb network after earlier follicular bumps. PMC+1

2. Unilateral or asymmetric pattern – one side is much more affected (rare, but reported). PMC

3. Early inflammatory phase – visible as tiny rough, skin-colored or red follicular bumps in childhood.

4. Atrophic (scarring) phase – later stage with shallow pits and net-like atrophy replacing the bumps. PubMed

5. Syndromic/associated pattern – when similar follicular atrophy appears alongside other inherited conditions (for example, within the broader keratosis pilaris atrophicans group, or rarely in association with connective-tissue gene changes). RePub+1

Causes

Atrophoderma vermiculata does not have one proven single cause for all people. Instead, many factors can contribute. Here are 20 plain-language contributors doctors consider:

1. Abnormal keratinization of the hair-follicle opening – the skin’s outer cells build up and plug the opening. This is the core process. DermNet®

2. Chronic perifollicular inflammation – long-lasting, low-grade inflammation around the plugged follicle. PubMed

3. Atrophy after inflammation – healing leaves shallow pits and thin skin around follicles. PubMed

4. Genetic predisposition – many cases run in families and sit within the inherited keratosis pilaris atrophicans spectrum. (The exact genes are not fully defined in AV.) RePub

5. Related keratosis pilaris biology – the same biology that causes common keratosis pilaris (plugged follicles) can, in rare individuals, progress to atrophy. DermNet®

6. Childhood onset – developing skin and hair follicles may be more vulnerable in early years. PubMed

7. Dry skin (xerosis) – dryness promotes plugging and rough bumps, which can fuel the cycle. DermNet®

8. Cold or low-humidity environments – these conditions worsen dryness and plugging. DermNet®

9. Sensitive skin barrier – a weaker barrier makes irritation and redness more likely around follicles. DermNet®

10. Skin micro-injury from scratching or rubbing – can prolong inflammation around follicles.

11. Secondary bacterial overgrowth in blocked follicles – sometimes worsens redness, though AV itself is not an infection.

12. Hormonal changes of childhood/adolescence – may influence hair and skin oil, nudging follicular plugging.

13. Coexisting atopy (dry, sensitive, or eczema-prone skin) – may amplify roughness and inflammation. DermNet®

14. Family history of keratosis pilaris atrophicans variants – supports a hereditary tendency. RePub

15. Uncommon genetic associations – rare reports link similar atrophicans patterns with certain gene pathways (for example, TGF-β signaling in related contexts), but these are not routine causes of AV. JAMA Network

16. Sun exposure – usually not a driver, but chronic sun can change skin texture and may make pits stand out more.

17. Oily or thicker follicular openings in some skin types – more prone to plugging.

18. Delayed shedding of the stratum corneum – slows natural “unclogging” of follicle openings. DermNet®

19. Low awareness and late care – when early bumps are not treated, long-term atrophy can quietly build. (Clinical observation; evidence is limited.)

20. Overlap variants – if someone has features of ulerythema ophryogenes (eyebrow thinning) or KFSD, the shared biology can intensify follicular atrophy, even if the exact label differs. RePub

Important note: many people want to know “the” gene or “the” trigger. Current medical literature says the mechanism is not fully understood, and AV is rare, so strong, one-size-fits-all causes have not been proved. ScienceDirect

Symptoms

1. Tiny rough bumps in early years – small, sometimes reddish or skin-colored follicle-centered bumps, especially on the cheeks. PubMed

2. Honeycomb or net-like pitting later – shallow pits replace bumps and line up to form a reticular pattern. Acta Marisiensis

3. “Worm-eaten” look on close view – the pits make a characteristic pattern under bright light. PMC

4. Cheek emphasis – the cheeks are the most affected site; the forehead and pre-auricular areas may also be involved. PMC

5. Usually symmetrical – both sides of the face are commonly involved; unilateral cases are unusual but possible. PMC

6. Onset in childhood – most people notice early changes in school-age years. PubMed

7. Minimal itch or pain – symptoms are mainly cosmetic; itching is usually mild or absent.

8. Background redness (erythema) in early phase – due to low-grade inflammation around follicles. Acta Marisiensis

9. Dry or rough skin feel – dryness and roughness are common. DermNet®

10. Stable course after a few years – the condition often stops progressing after adolescence. ScienceDirect

11. Occasional tiny white cysts or comedones – milia-like spots can appear in the area. Acta Marisiensis

12. Psychosocial impact – people may feel self-conscious about facial texture.

13. Eyebrow thinning is not typical in AV – that feature points more to the sibling condition ulerythema ophryogenes, but mild overlap can occur. RePub

14. No systemic illness – AV itself does not make you sick or cause fever or fatigue.

15. No scarring acne history needed – the pits can look like acne scars but usually occur without prior severe acne. ScienceDirect

Diagnostic tests

Big picture: Atrophoderma vermiculata is mostly a clinical diagnosis—meaning doctors recognize it from the history and how it looks. Tests are used to document features, rule out look-alikes (for example, acne scarring, varioliform scarring, or other keratosis pilaris atrophicans variants), and reassure the patient. Not all tests below are needed for every person.

A) Physical examination (typical bedside assessment)

1. Visual inspection in good light
   Your clinician looks for small pits forming a net-like or honeycomb pattern on the cheeks, often following an earlier phase of follicular bumps. The location and pattern are major clues. PubMed+1

2. Palpation of skin texture
   Gently feeling the area confirms fine roughness early on and shallow depressions later. Texture helps separate AV from purely pigmentary changes.

3. Mapping of distribution
   The cheeks and pre-auricular areas are noted; the forehead, chin, or temples may be involved. Symmetry supports the diagnosis; strong one-side involvement is recorded as an atypical pattern. PMC+1

4. Look for signs of active follicular plugging
   The clinician notes tiny follicular papules or scale that suggest ongoing plugging and inflammation—useful for guiding skin-care plans. DermNet®

5. Screen for sibling conditions
   Brows and scalp are checked: eyebrow thinning points more to ulerythema ophryogenes; scalp scarring points more to KFSD. This helps place the case within the “keratosis pilaris atrophicans” family. RePub

B) Manual office tests (simple chairside maneuvers or tools)

6. Skin stretching test
   Gently stretching the skin makes shallow pits and net-like depressions easier to see, improving documentation.

7. Diascopy (glass slide pressure)
   Pressing a clear slide briefly can reduce redness and show the true pit edges. This helps judge atrophy vs. color changes.

8. Standardized clinical photography
   Front and side photos under the same lighting track the pattern over time and after treatment trials.

9. Hair-pull test of eyebrows if overlap suspected
   While AV itself does not typically cause brow loss, a gentle pull test is done if brow thinning is seen, to check for a sibling condition.

C) Laboratory & pathological tests (used selectively)

10. Punch skin biopsy for histopathology
    A tiny skin sample can confirm the picture when the diagnosis is uncertain. Common findings include follicular plugging, hyperkeratosis, perifollicular inflammation early on, and later perifollicular fibrosis and atrophy. (Biopsy is not required in typical cases.) Acta Marisiensis+1

11. Special stains on biopsy (e.g., PAS)
    These can highlight keratin and follicular structures or look for unusual infections if clinically suspected. DermNet®

12. Tissue culture only if infection is suspected
    Cultures are rarely needed but may be taken if pustules or secondary infection appear (which is uncommon in AV).

13. Basic blood tests (CBC, inflammatory markers) as baseline
    Not diagnostic for AV but sometimes done to provide overall skin-health context or before procedures.

14. Genetic testing (targeted) in unusual or overlapping cases
    Most AV patients do not need genetic testing. In puzzling cases that look like other keratosis pilaris atrophicans variants or have features of inherited connective-tissue disorders, limited testing may be considered; results often do not show a single known “AV gene.” cureus.com

D) Device-based, “electro-/optic” and imaging-type assessments

15. Dermoscopy (handheld skin scope)
    Noninvasive magnified viewing can show follicular plugging, perifollicular scale, and the honeycomb arrangement of tiny pits. It helps document and distinguish AV from acne scarring. PMC

16. Trichoscopy (dermoscopy of hair-bearing areas)
    If brows or nearby hair are examined, trichoscopy can look for hair-shaft changes or perifollicular changes that suggest overlap conditions.

17. Reflectance confocal microscopy (if available)
    This noninvasive imaging can visualize superficial skin structures and support the clinical impression in research or specialty settings.

18. High-frequency ultrasound of skin (if available)
    May show thinning in the superficial dermis where the pits are. This is rarely necessary but can be used in centers that study scarring patterns.

19. Optical coherence tomography (OCT) of the skin (if available)
    Another noninvasive imaging method used in some dermatology units to map shallow atrophy.

20. Wood’s lamp examination
    Ultraviolet light may help highlight surface scale or subtle contrast in the honeycomb pattern; it does not diagnose AV by itself.

Note on “electrodiagnostic” tests: nerve-and-muscle electrical tests are not used for AV because it is a skin/follicle condition, not a nerve disorder. The device-based tools above are noninvasive optical imaging methods used in dermatology.

Non-pharmacological treatments (therapies & others)

(Evidence is limited; goals are to reduce roughness/redness and improve the look of scars. Each item: description, purpose, mechanism.)

1. Gentle non-soap cleansers – Daily washing with mild syndet cleansers reduces irritation and helps topical medicines work better. Purpose: keep the barrier intact and reduce follicular debris. Mechanism: fewer harsh surfactants → less barrier damage and less inflammation. DermNet®

2. Regular moisturising with keratolytic emollients – Creams containing urea, lactic acid, AHA, or salicylic acid soften plugs and smooth roughness. Purpose: decrease follicular scale. Mechanism: chemical keratolysis loosens compact keratin at follicle openings. DermNet®

3. Physical gentle exfoliation – Occasional use of a soft exfoliating sponge or pumice on bumpy areas. Purpose: remove surface plugs and improve feel. Mechanism: controlled mechanical debridement of keratin build-up. (Avoid over-scrubbing to prevent irritation.) DermNet®

4. Sun protection – Daily broad-spectrum sunscreen helps scars look less obvious and prevents color change. Purpose: reduce post-inflammatory dyspigmentation and photo-aging. Mechanism: UV protection preserves collagen and limits pigment shift around atrophic pits. MDedge

5. Camouflage techniques – Color-correcting primers and soft-focus makeup can hide textural changes. Purpose: immediate cosmetic improvement. Mechanism: optical diffusion and color balancing reduce perceived irregularities. (Expert consensus; no trials in AV.) MDedge

6. Counselling/psychosocial support – Visible facial scarring can affect self-esteem; brief counselling or support groups can help. Purpose: improve quality of life while medical care proceeds. Mechanism: coping strategies reduce distress. (General dermatology care principle.) MDedge

7. Dermoscopy-guided skin care – Using dermoscopy to monitor plugs/erythema helps tailor exfoliation and topicals. Purpose: individualise care. Mechanism: visualising follicular changes guides intensity of keratolysis. PMC

8. Pulsed Dye Laser (PDL) for erythema – In KPA variants, PDL can reduce redness and sometimes texture over multiple sessions. Purpose: lessen persistent erythema around follicles. Mechanism: selective photothermolysis of superficial vessels decreases inflammation. ResearchGate

9. 1064-nm Nd:YAG laser (select cases) – For keratosis pilaris (a related condition), Nd:YAG has emerging evidence and may help texture/erythema; used off-label for AV patterns when redness predominates. Purpose: smooth and reduce redness. Mechanism: deeper vascular/follicular effects with controlled thermal injury and remodeling. Oxford Academic

10. Fractional ablative laser resurfacing (e.g., CO₂/Er:YAG) – Case-based use to soften shallow pits and stimulate remodeling. Purpose: improve scar appearance. Mechanism: fractional microthermal zones trigger collagen remodeling and surface levelling. (AV-specific evidence limited; approach extrapolated from atrophic scar care.) ScienceDirect

11. Fractional non-ablative lasers (e.g., 1550–1540 nm) – Gentle remodeling for patients who need less downtime. Purpose: incremental texture improvement. Mechanism: dermal heating stimulates new collagen with minimal epidermal damage. (Low-level evidence in related scarring.) ScienceDirect

12. Microneedling – May soften shallow atrophic changes via controlled micro-injury and collagenesis. Purpose: texture refinement. Mechanism: needle-induced wound healing stimulates collagen/elastin. (No AV-specific trials.) MDedge

13. Dermabrasion/microdermabrasion – Historical options to plane superficial atrophy; now largely replaced by fractional lasers. Purpose: reduce pit edges. Mechanism: mechanical resurfacing promotes re-epithelialisation and smoother transition zones. ScienceDirect

14. Intralesional saline or normal-saline needling (select cases) – Very low-risk collagen induction technique used for superficial acne scars; sometimes extrapolated for AV pits. Purpose: improve contour. Mechanism: mechanical stimulation and minor wound healing. (Extrapolated; evidence limited.) MDedge

15. Silicone gel for contour irregularities (adjunct) – Softens edges and may improve light reflection; mainly supportive. Purpose: aesthetic blending. Mechanism: occlusion and hydration modulate keratinocyte signalling. (Expert practice; not AV-specific.) MDedge

16. Platelet-rich plasma (PRP) as adjunct to resurfacing – Considered in cosmetic dermatology for atrophic scars to speed healing; off-label for AV. Purpose: enhance remodeling and recovery after procedures. Mechanism: growth factors stimulate dermal repair. (Extrapolated evidence.) MDedge

17. Low-level laser/light therapy (LLLT) – May reduce redness and support healing after procedures; data are limited. Purpose: adjunctive symptom relief. Mechanism: photobiomodulation affects cellular metabolism and inflammation. (Limited evidence.) MDedge

18. Barrier-repair creams (ceramides/niacinamide) – Support daily care, reduce irritation from actives. Purpose: maintain skin barrier during long courses of retinoids/keratolytics. Mechanism: lipid replacement and anti-inflammatory effects. (General derm evidence.) MDedge

19. Avoid picking/squeezing – Prevents extra trauma and scarring around follicle openings. Purpose: reduce secondary scarring. Mechanism: minimises mechanical injury and post-inflammatory change. MDedge

20. Realistic cosmetic goal-setting – Early counselling that improvements are gradual and partial helps adherence. Purpose: sustained care and safer use of actives/procedures. Mechanism: expectation management improves outcomes. MDedge

Drug treatments

(AV has no approved drug cure. Most drug evidence is from case reports or extrapolated from KPA/keratosis pilaris care. Doses are typical dermatology starting points; individual dosing must be set by a clinician.)

1. Topical tretinoin 0.025–0.05% cream/gel nightly – Often first-line in KPA. Purpose: smooth plugs, support remodeling. Mechanism: normalises keratinisation and promotes collagen over time. Side effects: irritation, dryness, photosensitivity; avoid in pregnancy. Evidence: AV case with good response to topical tretinoin over 12 months. Synapse

2. Oral isotretinoin (e.g., 0.3–0.5 mg/kg/day for several months; clinician-directed) – For inflammatory/active phases when scarring is still evolving. Purpose: suppress follicular inflammation and keratinisation. Mechanism: reduces sebaceous activity and abnormal keratinisation. Side effects: teratogenicity, mucocutaneous dryness, lab changes. Evidence: case report remission of inflammatory component and halting of progression. PubMed

3. Topical adapalene 0.1% gel nightly – A gentler retinoid alternative. Purpose: reduce plugging with less irritation. Mechanism: retinoid receptor modulation. Side effects: mild irritation/photosensitivity. (Extrapolated from keratosis pilaris care.) DermNet®

4. Topical tazarotene 0.045–0.1% – Stronger retinoid for more resilient skin. Purpose: keratolysis and remodeling. Side effects: irritation; strict photoprotection. (Extrapolated; clinician judgment.) MDedge

5. Keratolytic creams (urea 10–20%) twice daily – Purpose: soften follicular plugs, smooth feel. Mechanism: humectant + keratolysis. Side effects: stinging on broken skin. DermNet®

6. Lactic acid (AHA 10–12%) or ammonium lactate 12% – Purpose: chemical exfoliation. Mechanism: loosens corneocyte cohesion. Side effects: sting, photosensitivity; introduce slowly. DermNet®

7. Salicylic acid 2–6% lotions – Purpose: comedolytic keratolysis for plugs. Mechanism: lipid-soluble keratolytic penetrates follicles. Side effects: irritation; avoid overlarge areas in children. DermNet®

8. Topical benzoyl peroxide 2.5–5% once daily – For mild inflammation around follicles. Mechanism: antibacterial and keratolytic. Side effects: dryness, bleaching of fabrics. (Suggested for KPA in observational series.) PMC

9. Topical corticosteroids (low-to-mid potency, short courses) – For visible erythema/inflammation flares. Mechanism: anti-inflammatory. Side effects: atrophy with overuse—use sparingly. (Symptom-driven adjunct.) MDedge

10. Topical calcineurin inhibitors (tacrolimus/pimecrolimus) – For steroid-sparing anti-inflammatory effect on facial skin. Mechanism: blocks T-cell activation. Side effects: transient burning. (General facial dermatitis practice; extrapolated.) MDedge

11. Azelaic acid 15–20% – Keratolytic and anti-inflammatory that can lessen roughness and pigment variation. Side effects: sting, dryness. (Extrapolated from KP/acne care.) MDedge

12. Topical niacinamide 2–5% – Barrier-support and anti-inflammatory. Side effects: rare irritation. (Adjunct; general derm evidence.) MDedge

13. Short-course oral tetracyclines (e.g., doxycycline 50–100 mg/day) – If there is a prominent inflammatory papular phase. Mechanism: anti-inflammatory effects in skin. Side effects: photosensitivity, GI upset. (Extrapolated; clinician-directed.) MDedge

14. Topical calcipotriol (vitamin D analogue) – Rarely used adjunct aiming at keratinisation control. Side effects: irritation. (Sparse data; clinician discretion.) MDedge

15. Clindamycin/benzoyl peroxide combos – For mixed follicular inflammation patterns. Mechanism: antibacterial plus keratolysis. Side effects: dryness; resistance concerns mitigated by BPO. (Extrapolated.) MDedge

16. Topical retinoid + keratolytic rotation – Alternating retinoid nights with urea/AHA nights improves tolerance and consistency. Purpose: maintain long-term smoothing. (Expert practice pattern.) DermNet®

17. Procedural adjuvants: topical anaesthetics – For comfort during resurfacing/needling. Mechanism: sodium channel blockade. (Procedural standard.) ScienceDirect

18. Post-procedure barrier/healing ointments – Protects epidermis after lasers/needling. Mechanism: occlusion, moisture retention. (Procedural standard.) ScienceDirect

19. Sunblock with iron oxides (tinted) – Protects and color-corrects inflammatory pigment. Mechanism: UVA/UVB/visible light protection. (Cosmetic dermatology standard.) MDedge

20. Topical silicone-based primers – As a pharmacologic-cosmetic hybrid to visually blur pits while medical therapy acts. Side effects: minimal. (Adjunct.) MDedge

Important safety note: Only isotretinoin and topical retinoids have direct AV case-level evidence; most other drugs are supportive or extrapolated from related KPA/KP care. Always individualise with a dermatologist. PubMed+1

Dietary molecular supplements

There are no supplements proven to treat AV specifically. The options below support general skin barrier or inflammation control. Discuss with your clinician, especially with retinoids/prescriptions.

1. Ceramide-precursor lipids (topical/oral ceramides) – May improve barrier hydration; useful alongside actives to reduce irritation. Mechanism: restores stratum corneum lipids. (General derm care; no AV-specific trials.) MDedge

2. Niacinamide (oral low-dose or topical 2–5%) – Anti-inflammatory and barrier-support; may reduce redness and sensitivity from actives. Mechanism: decreases inflammatory mediators and TEWL. MDedge

3. Omega-3 fatty acids – Systemic anti-inflammatory benefits that can help reactive skin; watch for bleeding risks at high dose. Mechanism: eicosanoid pathway modulation. (General skin health data; none specific to AV.) MDedge

4. Vitamin D (correct deficiency only) – Low vitamin D is common and correcting it supports immune balance/keratinisation; avoid excess. Mechanism: nuclear receptor effects on keratinocytes. (No AV-specific trial.) MDedge

5. Zinc (if deficient) – Supports skin healing and reduces inflammation; excess can cause copper deficiency. Mechanism: cofactor in epithelial repair. (General derm.) MDedge

6. Probiotics (general skin support) – May modulate inflammation/skin barrier via gut-skin axis; strain-specific effects vary. (No AV-specific data.) MDedge

7. Collagen peptides – Some evidence for improved skin elasticity/texture in photoaging; adjunct at best for pits. Mechanism: peptide signalling and dermal matrix support. (Not AV-specific.) MDedge

8. Hyaluronic acid (oral/topical) – Hydration support to reduce visibility of fine textural changes. Mechanism: humectancy and ECM interactions. (Adjunct.) MDedge

9. Green tea polyphenols (EGCG) – Anti-inflammatory/antioxidant properties; may calm erythema. Mechanism: NF-κB modulation. (Adjunct.) MDedge

10. Avoid high-dose vitamin A supplements while on retinoids – Prevent additive toxicity; stick to diet-level intake unless clinician directs otherwise. (Safety guidance.) PubMed

Immunity-booster / regenerative / stem-cell drugs

There are no validated immunity boosters, regenerative medicines, or stem-cell drugs for AV. Using such agents outside clinical trials can be risky and is not recommended. The most evidence-supported systemic option for active AV is oral isotretinoin, which is not an immune booster but a retinoid that normalises follicular keratinisation and reduces inflammation. Safer “regenerative” approaches are fractional lasers, microneedling, and PRP as procedural adjuncts, which trigger the body’s own collagen remodeling—not stem-cell drug therapy. If you see clinics offering stem-cell shots for AV, ask for peer-reviewed evidence; currently there isn’t credible, AV-specific data. PubMed+1

Surgeries/procedures

1. Fractional CO₂/Er:YAG laser resurfacing – Outpatient sessions create micro-columns of ablation to stimulate new collagen and smooth shallow pits. Why: best-studied option for atrophic texture in many settings; used off-label in AV due to similar scar biology. ScienceDirect

2. Pulsed Dye Laser (PDL) – Non-ablative vascular laser targets redness around follicles; multiple sessions needed. Why: reduces erythema/inflammation in KPA variants and may subtly improve texture. ResearchGate

3. Nd:YAG laser (select cases) – For deeper vascular/follicular targets with modest downtime. Why: growing evidence in keratosis pilaris; sometimes chosen when redness and textural change coexist. Oxford Academic

4. Dermabrasion (classic) or microdermabrasion – Mechanical planing of the superficial skin to soften pit edges. Why: legacy option; now less common but can help in thin, very superficial atrophy. ScienceDirect

5. Microneedling ± PRP (adjunct) – Repeated sessions to induce collagen, sometimes combined with topical growth factors. Why: minimally invasive remodeling for shallow atrophy when lasers are not preferred. MDedge

Practical prevention & self-care tips

1. Daily gentle cleanser and moisturiser; avoid harsh scrubs. Why: protects barrier and reduces irritation. DermNet®

2. Sun protection (SPF 50+, hats). Why: prevents dyspigmentation and scar accentuation. MDedge

3. Introduce actives slowly (retinoids/keratolytics) and moisturise to tolerance. Why: improves adherence and results. DermNet®

4. Don’t pick/squeeze bumps. Why: prevents extra scarring. MDedge

5. Use tinted, iron-oxide sunscreens or cosmetic primers if redness bothers you. Why: optical masking + visible light protection. MDedge

6. Consider short procedural series (laser/needling) during cooler months to simplify sun care. Why: lowers PIH risk. ScienceDirect

7. Keep expectations realistic and review progress every 3–4 months. Why: changes are gradual. MDedge

8. Protect skin from wind/cold with richer emollients. Why: reduces scaling and roughness. DermNet®

9. Coordinate isotretinoin with a dermatologist if chosen; use pregnancy prevention plans as required. Why: strict safety rules. PubMed

10. If redness is your main concern, ask about PDL first. Why: vascular targeting can help even when texture shifts slowly. ResearchGate

When to see a doctor

See a dermatologist early if facial bumps are spreading, if new honeycomb-like pits appear, or if redness persists. Early care with topicals may reduce plugging, and procedures can be planned for later to improve the appearance of pits. Urgently discuss oral isotretinoin only when there’s an active inflammatory phase, and learn the lab monitoring and contraception requirements. Ask about associated syndromes if there’s a family history of sparse hair, multiple milia, unusual facial telangiectasia, or early basal cell carcinomas. DermNet®+3Synapse+3PubMed+3

What to eat and what to avoid (simple guidance)

No diet cures AV, but a balanced, anti-inflammatory diet helps skin recovery from procedures and tolerating topical treatments. Aim for whole foods, lean proteins, fruits/vegetables, omega-3-rich fish, and adequate hydration. Limit ultra-processed foods, excess sugars, and high-dose vitamin A supplements (especially if using retinoids). If you have any nutrient deficiency (e.g., vitamin D or zinc), correct it with your clinician’s guidance. PubMed+1

FAQs

1) Is AV dangerous?
No. AV is benign. The main issue is cosmetic scarring/texture and sometimes redness. MDedge

2) Will it spread forever?
It often stabilises after adolescence/young adulthood, though established pits may persist. MDedge

3) Can creams remove the pits completely?
Creams (retinoids, keratolytics) soften plugs and edges but usually do not erase pits; procedures help more for texture. Synapse+1

4) Is isotretinoin ever used?
Yes, in selected cases with active inflammation; case reports show halting progression. Requires strict monitoring. PubMed

5) Which laser should I ask about first?
If redness stands out: PDL. For pits: consider fractional resurfacing. Plans are individual. ResearchGate+1

6) Is AV related to keratosis pilaris?
Yes—AV is a KPA spectrum disorder with follicular plugging and atrophy. MDedge

7) Can AV be part of a syndrome?
Rarely, with Rombo or Bazex-Dupré-Christol syndromes, among others; most cases are not syndromic. Semantic Scholar+1

8) Do supplements help?
No supplement is proven for AV; focus on barrier support and overall nutrition. MDedge

9) Will shaving or hair removal worsen it?
Gentle methods usually do not; avoid traumatic techniques that irritate follicles. MDedge

10) Can makeup be used?
Yes—tinted sunscreens/primers can camouflage texture safely. MDedge

11) Is it contagious?
No. It is not an infection. MDedge

12) How long before I see improvement?
Topicals may take 8–12 weeks for feel/redness; procedures show gradual gains over several months. Synapse+1

13) Do children need different care?
Yes—use gentler strengths, avoid strong keratolytics over large areas, and get specialist guidance. DermNet®

14) What about scarring prevention?
Early control of plugging/inflammation plus photoprotection and no picking helps limit new pits. DermNet®+1

15) Are there clinical trials?
None specific to AV at present; treatments are adapted from KPA/KP/scar care and case reports. MDedge

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 28, 2025.

Previous

Atrophoderma of Pasini and Pierini (APP)

Next

Folliculitis Ulerythematosa Reticulata (FUR)